Denali Therapeutics
Develops brain-penetrating therapies and commercializes AVLAYAH for Hunter syndrome.
$24.00
After-hours close+0.01 (+0.04%)
At close$23.99(−2.76%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 101.59%Insiders 5.44%
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 158.71M · Float 148.71M · 93.7% free float
Institutions13F, as of Jun 30, 2026
301 holders · 161.23M shares · 57 new positions · 182 increased · 66 reduced · 32 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 16.18M | 10.19% | +7.66M | Aug 14, 2026 |
| BlackRock, Inc. | 14.03M | 8.84% | +992.0K | Aug 7, 2026 |
| Baillie Gifford & Co | 11.96M | 7.54% | −106.2K | Aug 6, 2026 |
| State Street Corp | 7.05M | 4.44% | +777.3K | Aug 7, 2026 |
| Temasek Holdings (Private) Ltd | 7.01M | 4.42% | 0 | Aug 7, 2026 |
| Vanguard Portfolio Management LLC | 6.48M | 4.08% | +356.9K | Aug 13, 2026 |
| Vanguard Capital Management LLC | 6.28M | 3.95% | +127.8K | Aug 13, 2026 |
| FMR LLC | 4.54M | 2.86% | −39.5K | Aug 13, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Baillie Gifford & Co | 8.60% | 12.31M | 13G | Feb 12, 2025 ↗ |
| BlackRock, Inc. | 7.20% | 10.49M | 13G | Apr 17, 2025 ↗ |
| T. Rowe Price Investment Management, Inc. | 5.40% | 8.52M | 13G | May 15, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Baker Bros. Advisors LP | director | 3.42M | 2.16% | Jun 5, 2026 |
| Ryan J. Watts | director, officer: President and CEO | 2.42M | 1.52% | Aug 14, 2026 |
| Marc Tessier-Lavigne | director | 1.89M | 1.19% | Jun 5, 2025 |
| Alexander O. Schuth | officer: COFO and Secretary | 281.8K | 0.18% | Aug 13, 2026 |
| Carole Ho | officer: Chief Medical Officer | 216.6K | 0.14% | Aug 14, 2025 |
| Peter Scott Chin | officer: Chief Medical Officer | 204.4K | 0.13% | Apr 21, 2026 |
| Steve E. Krognes | director | 38.2K | 0.02% | Jun 5, 2026 |
| Peter S. Klein | director | 33.9K | 0.02% | Jun 5, 2026 |
| Jennifer E. Cook | director | 32.5K | 0.02% | Jun 5, 2026 |
| Nancy Thornberry | director | 31.1K | 0.02% | Jun 5, 2026 |
6 ten-percent owners hold 45.88M shares by Form 4, outside the officers-and-directors figure above · 4 people have not refiled in the last 18 months (164.0K shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 11, 2026 | Alexander O. Schuthofficer: COFO and Secretary | Sale | 2,857 | $25.07 | 281,763 |
| Jan 6, 2026 | Alexander O. Schuthofficer: COFO and Secretary | Sale | 17,218 | $16.50 | 282,828 |
| Jan 6, 2026 | Ryan J. Wattsdirector, officer: President and CEO | Sale | 35,198 | $16.50 | 296,833 |
| Dec 11, 2025 | Baker Bros. Advisors LPdirector | Purchase · 2 lots | 2,285,714 | $0.0100 | 25,996,310 |
CongressHouse and Senate disclosures
Not reported.